Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological diseases. Its mission focuses on addressing the unmet needs of patients with conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Biogen's strategy emphasizes cutting-edge research, collaboration with academic institutions, and leveraging advanced technologies to enhance drug development. The company operates through a robust pipeline of therapies and a commitment to patient-centric solutions, aiming to improve the quality of life for individuals affected by debilitating neurological disorders.

BIOGEN INC

Biogen is facing significant challenges as it moves into 2025, with its profit forecast falling below Wall Street expectations amid a strong dollar and increased competition in the multiple sclerosis (MS) market. Following its fourth-quarter earnings conference call on February 12, 2025, the company announced adjusted earnings per share (EPS)...

Biogen Faces Investor Disappointment as 2025 Profit Forecast Falls Short of Expectations Amid MS Drug Competition and Currency Challenges